- Home
- GGAL vs ROIV Comparison
GGAL vs ROIV Comparison
Compare GGAL & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GGAL | ROIV |
|---|---|---|
| Founded | 1905 | 2014 |
| Country | Argentina | United Kingdom |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2B | 14.1B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | GGAL | ROIV |
|---|---|---|
| Price | $48.76 | $21.94 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $75.67 | $21.94 |
| AVG Volume (30 Days) | 1.5M | ★ 6.5M |
| Earning Date | 01-01-0001 | 11-10-2025 |
| Dividend Yield | ★ 2.02% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.35 | N/A |
| Revenue | ★ $3,630,934,738.00 | $20,329,000.00 |
| Revenue This Year | $9.49 | N/A |
| Revenue Next Year | $13.17 | $376.94 |
| P/E Ratio | $14.88 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $25.89 | $8.73 |
| 52 Week High | $74.00 | $22.45 |
Technical Indicators
Market Signals| Indicator | GGAL | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 46.91 | 68.21 |
| Support Level | $48.75 | $20.14 |
| Resistance Level | $50.75 | $21.48 |
| Average True Range (ATR) | 2.38 | 0.66 |
| MACD | -0.67 | -0.02 |
| Stochastic Oscillator | 37.24 | 87.12 |
Price Performance
Historical ComparisonAbout GGAL Grupo Financiero Galicia S.A.
Grupo Financiero Galicia SA is a financial service holding company. It provides general banking services, proprietary brand credit card services, personal loans, insurance, and other services. The company's operating business segments are Banks, Ecosistema Naranja X, Insurance, Adjustments, and Other Businesses. It generates maximum revenue from Banks. Geographically its operate in Argentina, Uruguay, and the majority of its revenue comes from Argentina.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.